OC
Ocular Therapeutix, Inc.
OCUL · NASDAQ
$9.99 -1.58% (-$0.16)
1M -7.33%
Market Cap $2.22B
P/E Ratio -
Div. Yield -
ROE 59.87%
Bulios Fair Price
$13.69
37.0% upside
Current Price
$9.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OCUL is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
24 /100
Expensive P/S 42.65x
P/B 4.27x
P/E N/A
Growth
39 /100
Stable Rev. growth 0.21%
Book val. growth 164.45%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 87.11%
Net margin 579.10%
FCF margin 490.07%
Quality
1 /100
Poor ROIC 50.20%
ROE 59.87%
Asset turnover 0.08x
Debt
69 /100
Low Debt/Equity 0.15x
Current ratio 13.11x
Int. coverage -25.44x
Stability
73 /100
Stable Beta 0.97x
Rev. volatility 17.43%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OCUL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Pravin U. Dugel
Employees
325
Headquarters
Bedford
Upcoming events
03 NOV
Earnings
Upcoming earnings report